###### Strengths and limitations of this study

-   This is the first systematic review summarising statistical methods used in projecting lung cancer incidence or mortality rates over the past three decades.

-   The review was conducted according to the published guidelines.

-   Using predefined assessment criteria and a standardised data extraction form resulted in a high level of agreement in the data extractions performed by two independent reviewers.

-   The review provided theoretical and practical information, including a comprehensive summary of the methods and relevant software.

-   Meta-analysis was not possible due to the wide variation in study populations and time periods used in the projections.

Introduction {#s1}
============

Lung cancer has been the most commonly diagnosed cancer in the world for several decades and is the leading cause of cancer deaths worldwide, accounting for nearly 20% of all cancer deaths.[@R1] Reliable projections of future patterns of lung cancer incidence and mortality are, therefore, of importance for the planning of health service requirements and the management of healthcare resources.[@R2] Given the well-documented association between tobacco smoking and lung cancer risk,[@R4] projections of lung cancer incidence and mortality are also important for evaluating the effectiveness of existing tobacco control programme and the forward projection of the potential impact of new evidence-based tobacco control strategies.[@R2] There have been a variety of statistical methods developed and reported in the literature for projecting cancer incidence or mortality rates.[@R2] These methods range from assuming the current rate remains unchanged into the future, to a more complex class of statistical models of past trends such as age--period--cohort (APC) models, which may involve a range of assumptions, software and techniques.

Projecting future cancer incidence and mortality trends is always a complex exercise due to the changing risk factor profiles over time, and the long latency period between risk factor exposure and development of some cancers.[@R8] For lung cancer in particular, projections can be inaccurate if any changes in past smoking behaviour are not accurately taken into account.[@R2] Unfortunately, data on smoking behaviour are not always available with the requisite level of detail (eg, sex-age-specific data), so choosing and implementing an appropriate projection method largely depends on data availability and the purpose for the projections.[@R8] Given the complexity involved in such projections, information on the available statistical methods, utilisation of these methods and further developments in this area are of particular interest to researchers working in this field. However, while some of these methods have been reviewed and evaluated,[@R8] to our knowledge, there are currently no published systematic reviews of all statistical methods available for projecting lung cancer incidence or mortality rates.

Therefore, we carried out a methodological systematic review to identify and summarise published population-based studies that used statistical methods to project lung cancer incidence or mortality rates over the long term (eg, more than 5 years). The aim was to provide up-to-date and comprehensive information on the statistical methods that are available for projecting lung cancer rates. In doing so, our intention was to provide readers with an understanding of these various statistical methods, the availability of statistical software to implement these methods, and the utilisation of these methods in different circumstances, and to highlight the differences and similarities between methods.

Methods {#s2}
=======

This systematic review adhered to the checklist presented in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses.[@R12] A protocol was developed for this review and is included as [online supplementary resource 1](#SP1){ref-type="supplementary-material"}.
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Patient and public involvement {#s2-1}
------------------------------

As this was a systematic review of statistical methods used to obtain lung cancer rate projections, no patients or public were involved.

Literature search {#s2-2}
-----------------

In August 2016, Embase, Medline and PreMEDLINE databases were searched using text terms and, where available, database-specific subject headings, for studies published since 1988, which used statistical methods to project lung cancer incidence and/or mortality. Searches for lung cancer-related terms were combined with searches for terms related to projection, forecasting and statistical models. Reference lists of relevant articles were checked for additional potentially relevant articles. In August 2018, Embase and Medline, including Epub Ahead of Print, In-Process and other Non-Indexed Citations databases, were searched for studies published from 2016 onwards using an updated search strategy, which aimed to capture all newly published articles. A complete list of the terms used is included in [online supplementary resource 2](#SP2){ref-type="supplementary-material"}.
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Selection criteria {#s2-3}
------------------

Full inclusion and exclusion criteria are listed in [table 1](#T1){ref-type="table"}. Studies were included if they used a statistical method to project lung cancer incidence and/or mortality over a period greater than 5 years using population-based data and were published in English from 1 January 1988 to 14 August 2018. 'Statistical method' was defined as a method that analyses the observed data using traditional regression, correlation or other statistical summaries. 'Projection' was defined as the use of data including the whole or part of the observed data to forecast lung cancer incidence or mortality rates beyond the time period covered by the data included in the statistical models. Mathematical models, which generate outcomes based on a proposed theoretical model of the disease's natural history, were not included in this review.

###### 

Inclusion and exclusion criteria employed

  Domain                  Inclusion criteria                                                                                                                                             Exclusion criteria
  ----------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------
  Study type              Population-based original research studies                                                                                                                     Any of: Editorial comment, literature review, case studies, clinical trials, case--control studies.
  Study population        General population in any country                                                                                                                              Restricted to selected groups, that is, selected patients with cancer or high-risk populations.
  Outcomes                Reports projections of lung cancer incidence and/or mortality rates                                                                                            No relevant outcomes are reported, that is, no lung cancer-specific outcomes.
  Statistical method      Uses a statistical method for the projection, including studies, which used simulation methods to estimate confidence intervals, that is, Bayesian technique   Uses mathematical models, which generate outcomes based on a proposed theoretical model of the disease's natural history.
  No of years projected   Reports long-term projections, that is, greater than 5 years                                                                                                   Does not report projections of lung cancer rates, that is, only explains past trends, or reports projections less than or equal to 5 years.
  Publication type        Full-text published                                                                                                                                            Conference proceedings, abstracts, posters.
  Time of publication     Published from 1 January 1988 to 14 August 2018                                                                                                                Published before 1988.
  Language                English                                                                                                                                                        Language other than English.

Application of selection criteria {#s2-4}
---------------------------------

The literature search and the review followed the stages described in [figure 1](#F1){ref-type="fig"}. After removing duplicates, 1878 studies were retained for screening. One author (SH) screened the titles and abstracts against the inclusion criteria to exclude articles that were clearly irrelevant. The main reason for exclusion of papers at the screening stage was that the studies did not report on lung cancer incidence or mortality. Others were excluded because they used mathematical methods rather than being population-based studies. Further studies were excluded because they were an editorial commentary or literature review. After the screening process, a total of 166 studies were eligible for full-text review.

![PRISMA flow chart of study selection process. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.](bmjopen-2018-028497f01){#F1}

Full-text articles were independently reviewed and assessed for inclusion by two authors (XQY and QL) and a total of 101 studies were retained for final inclusion (92% agreement). Disagreements were discussed and if an agreement could not be reached the study was assessed for inclusion by a third reviewer (DLO). Excluded studies and the reasons for exclusion are listed in [online supplementary resource 3](#SP3){ref-type="supplementary-material"}. The main reasons for exclusion of studies at this stage were that they did not report lung cancer rates separately or the projections were for fewer than 6 years.
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Critical appraisal {#s2-5}
------------------

As the purpose of this methodological review was to provide an overview of statistical methods, and the projections of lung cancer rates were conducted in different populations and over different time periods, no meta-analysis was possible and specific projection results were not compared or analysed in this review. Therefore, the risk of bias evaluation of the included studies was not applicable.

The methodological quality of the studies was independently assessed by two reviewers using prespecified criteria ([table 2](#T2){ref-type="table"}): quality of the data source, length of period covered by the observed data, availability of software information, model fitting and validation. Validation provides information on the performance and reliability of the projection model and can be undertaken by withholding the most recent observed data from the model fitting and then comparing the projected rates for those years with the actual observed values.[@R7] As the use of scales for assessing study quality is discouraged in Cochrane reviews[@R13] and meta-analyses,[@R14] as the calculation of an overall score inevitably involves assigning (often arbitrary) weights to the quality criteria being assessed. It is difficult to justify the weights used and it has been shown that the overall quality score is not a reliable assessment of the study's validity.[@R13] Moreover, each method included in this review has its own merits and limitations, and depending on specific circumstances may be more or less reliable or relevant. Therefore, an overall score for the methodological quality of each study was not provided.

###### 

Prespecified criteria for assessing studies included in this review

  Criterion                                    Yes                                                                                                                                                                                                                                                                                                                   No or not clear
  -------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Strengths                                                                                                                                                                                                                                                                                                                                                          
   ≥10 years observed data                     Observed data period reported ≥10 years.                                                                                                                                                                                                                                                                              Observed data period reported \<10 years, or there is insufficient information to make an assessment.
   Good quality data source                    Data source reported, and the majority of observed data used are included in IARC Cancer in Five Continents, or with high population coverage as stated in WHO database.                                                                                                                                              Data source reported but the majority of observed data used are not included in IARC Cancer in Five Continents, or with low population coverage as stated in WHO database, or there is insufficient information to make an assessment.
   Provided fitted values of observed data     Reports both model estimates and observed data for the period used for model fitting.                                                                                                                                                                                                                                 Does not report both model estimates and observed data for the period used for model fitting.
   Validated projections using observed data   The model was validated by excluding data for the most recent years from the model fitting, and then comparing the projected rates for those years with the observed data. Provides both model projections beyond the period included in model fitting and a comparison with the observed data for the same period.   Does not provide validation using observed data.
  Advantage                                                                                                                                                                                                                                                                                                                                                           
   Provided software information               Software information was described or referenced.                                                                                                                                                                                                                                                                     Software information not provided.

IARC, International Agency for Research on Cancer; WHO, World Health Organization.

Data extraction {#s2-6}
---------------

For each included study, two reviewers (XQY and QL) independently extracted details of the study including data sources, study population, year of publication, observed data period for the projections, statistical methods and software used, and whether the method incorporated information about smoking patterns, which is the main risk factor for lung cancer. The extracted data were collected using a standardised form (see [online supplementary resource 4](#SP4){ref-type="supplementary-material"}), which was pilot tested using 10 studies. Any differences between the two reviewers were discussed and when agreement could not be reached the studies were assessed by a third reviewer (DLO). The overall agreement between the two reviewers was 91.6%.

10.1136/bmjopen-2018-028497.supp4

The selection of an appropriate statistical method for projecting cancer rates is largely restricted by the quality and availability of cancer data, which is generally better in more developed countries.[@R15] The Human Development Index (HDI), developed by the United Nations,[@R16] is a summary measure of life expectancy, education and gross domestic product per head of population. We, therefore, recorded HDI ranking for each of the study populations, so that we could describe the distribution of projections methods used according to the country's level of development.

Classification of statistical methods {#s2-7}
-------------------------------------

In order to summarise the differences and similarities between the methods reported, we developed an organisational framework to classify methods into groups according to both the type of observed data used and the statistical models reported ([figure 2](#F2){ref-type="fig"}). As tobacco exposure is well known to be the most significant risk factor for lung cancer[@R4] and can be used as an important predictor for lung cancer incidence and mortality, we first divided the studies into two large categories according to whether or not they included data on smoking in the projection method. For each category, we then subdivided studies into groups according to the projection method used. Methods not incorporating data on smoking in the population were grouped as either: (1) APC models, a special form of generalised linear model (GLM), which includes age, period and cohort components, (2) other GLMs, where the number of cases (deaths) or the logarithm of this was modelled as a linear or non-linear function of the explanatory factors using the logarithm of the population size as an offset, with Poisson or negative binomial distribution and (3) present state method (eg, assumes that the age-specific rates in the future will be the same as the most recent observed rates, or assumes a constant annual rate of change as observed in a selected time period). Methods incorporating data on smoking were grouped into: (1) GLMs with a smoking variable as one of the covariates, (2) APC models that included an effect for smoking, (3) projections adjusted for the smoking attributable fraction (SAF) and (4) other methods (including all methods that do not use detailed historical cancer data or do not include detailed data on smoking). More detailed descriptions of each of these methods are provided in [online supplementary resource 5](#SP5){ref-type="supplementary-material"}.
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![Organisational framework to categorise methods for lung cancer mortality projections. APC, age--period--cohort; GLM, generalised linear model; SAF, smoking attributable fraction.](bmjopen-2018-028497f02){#F2}

Results {#s3}
=======

A total of 101 eligible studies were included ([table 3](#T3){ref-type="table"}). All these studies are ecological studies that used single year or 5-year aggregated population incidence or mortality data, or are based on cancer rates reported in the literature. [Table 4](#T4){ref-type="table"} shows the study characteristics grouped according to the method used for the projections. Eighty-eight studies used projection methods not incorporating data on smoking,[@R1] 16 studies used a method incorporating data on smoking,[@R3] and 6 studies used multiple methods.[@R18] Overall, APC models were the most commonly used method to project lung cancer rates (44 studies used this method),[@R2] and other GLMs were the next most commonly used (35 studies).[@R18] Only 12 studies used the present state method by assuming that the average cancer rates in the most recent years will remain constant into the future.[@R1] Of the 16 studies incorporating data on smoking, eight studies directly used GLMs with a variable reflecting detailed historical smoking-related behaviour as one of the covariates included.[@R3] These variables included number of cigarettes consumed and average tar content,[@R3] smoking prevalence,[@R111] number of years of smoking[@R106] and smoking intensity.[@R103] Two studies used APC models and predefined coefficients based on recent trends in smoking prevalence and tar content to adjust the estimates for the period parameter.[@R41] Two studies made projections adjusted for the SAF, which required limited data on smoking behaviour,[@R102] and the remaining four studies used other methods, which required limited data on both cancer rates and smoking behaviour.[@R104]

###### 

Summary of included studies

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author and year                  Lung cancer outcome(s)   Country                        Observed data   No of years projected   Incorporated smoking data                              Model                                                    Software                  Good data quality\*   Provides fitted values†   Validation‡
  -------------------------------------- ------------------------ ------------------------------ --------------- ----------------------- ------------------------------------------------------ -------------------------------------------------------- ------------------------- --------------------- ------------------------- -------------
  AIHW 2012[@R59]                        Incidence                Australia                      1982--2007      10--19 years            No                                                     Joinpoint analysis/GLM                                   Joinpoint                 Yes                   Yes                       No

  Alonso 2018[@R17]                      Incidence                Uruguay                        1990--2014      20+years                No                                                     APC model                                                Stata, R, Nordpred        No                    No                        No

  Arslanhan 2012[@R110]                  Incidence/\              Turkey                         2002            20+years                Yes, smoking prevalence and smoking status             Relative risk                                            Not provided              No                    No                        No
                                         mortality                                                                                                                                                                                                                                                                                 

  Baade 2012[@R90]                       Incidence                Australia                      1982--2007      10--19 years            No                                                     Assume same rate                                         Not provided              Yes                   No                        No

  Bashir 2001[@R2]                       Incidence/\              Finland                        1955--1974      20+years                No                                                     Bayesian APC model                                       WinBUGs                   Yes                   Yes                       Yes
                                         ortality                                                                                                                                                                                                                                                                                  

  Bosetti 2012[@R18]                     Mortality                32 European countries          1970--2009      \<10 years              No                                                     Bayesian APC model /Joinpoint analysis                   Joinpoint, GLIM           Yes                   No                        No

  Bray 2012[@R60]                        Incidence/\              184 countries                  1988--2002      20+ years               No                                                     GLM/annual percentage change                             Not provided              Yes                   No                        No
                                         mortality                                                                                                                                                                                                                                                                                 

  Brenner 1992[@R61]                     Incidence                Germany                        1968--1987      10--19 years            No                                                     GLM                                                      GLIM                      Yes                   No                        No

  Brown 1988[@R3]                        Mortality                USA                            1958--1982      20+ years               Yes, smoking prevalence, consumption and tar content   GLM with smoking as a covariate                          Not provided              Yes                   Yes                       No

  Byers 2006[@R62]                       Mortality                USA                            1990--2002      10--19 years            No                                                     GLM/assume same rate                                     Not provided              Yes                   No                        No

  Cancer Institute 2016[@R63]            Incidence/\              Australia                      1994--2008      10--19 years            No                                                     GLM                                                      SAS                       Yes                   No                        No
                                         mortality                                                                                                                                                                                                                                                                                 

  Cancer Projections Network 2010[@R9]   Incidence/\              Canada                         1975--1994      10--19 years            No                                                     Bayesian APC model/GAM                                   Nordpred, WinBUGs, GLIM   Yes                   Yes                       Yes
                                         mortality                                                                                                                                                                                                                                                                                 

  Carson 1993[@R64]                      Mortality                USA                            1979--1989      10--19 years            No                                                     GLM/assume same rate                                     BMDP                      Yes                   No                        No

  Castro 2016[@R65]                      Incidence                Portugal                       1994--2009      10--19 years            No                                                     Joinpoint analysis and GLM                               Stata, Joinpoint          Yes                   No                        No

  Cayuela 2011[@R19]                     Mortality                Spain                          1979--2008      20+ years               No                                                     APC model                                                Nordpred                  Yes                   No                        No

  Chen 2011[@R20]                        Incidence                China                          1998--2007      10--19 years            No                                                     Bayesian APC model                                       BAMP                      No                    No                        No

  Clements 2005[@R21]                    Mortality                5 countries                    1950--2001      10--19 years            No                                                     Bayesian APC model                                       R, WinBUGs                Yes                   Yes                       Yes

  Clèries 2016[@R22]                     Mortality                Spain                          1998--2012      10--19 years            No                                                     Bayesian APC model                                       INLA                      Yes                   No                        No

  Clèries 2018[@R23]                     Incidence/\              Spain                          1994--2013      10--19 years            No                                                     Bayesian APC model                                       Not provided              Yes                   No                        No
                                         mortality                                                                                                                                                                                                                                                                                 

  Coupland 2010[@R24]                    Incidence                UK                             1985--2003      20+ years               No                                                     APC model                                                Nordpred                  Yes                   No                        No

  Davis 2013[@R102]                      Incidence/\              USA                            1990--2007      10--19 years            Yes, smoking prevalence                                Annual percentage change and SAF                         SAS                       Yes                   No                        No
                                         mortality                                                                                                                                                                                                                                                                                 

  Didkowska 2009[@R66]                   Mortality                Poland                         1998--2006      10--19 years            No                                                     GLM                                                      Stata                     No                    No                        No

  D\'Souza 2013[@R91]                    Mortality                India                          2001--2004      20+ years               No                                                     Assume same rate                                         Not provided              No                    No                        No

  D\'Souza 2013b[@R92]                   Incidence                India                          2001--2004      20+ years               No                                                     Assume same rate                                         Not provided              No                    No                        No

  Dušek 2015[@R67]                       Incidence                Czech Republic                 1978--2011      \<10 years              No                                                     GLM                                                      S                         Yes                   No                        No

  Dyba 1997[@R68]                        Incidence                Sweden                         1960--1984      20+ years               No                                                     GLM                                                      GLIM                      Yes                   No                        No

  Dyba 2000[@R69]                        Incidence                Finland                        1954--1978      10--19 years            No                                                     GLM                                                      GLIM                      Yes                   No                        Yes

  Eilstein 2008[@R25]                    Mortality                France                         1978--2002      10--19 years            No                                                     Bayesian APC model                                       WinBUGs                   Yes                   No                        No

  Eilstein 2012[@R26]                    Mortality                France                         1977--2006      10--19 years            No                                                     Bayesian APC model/GAM                                   R, WinBUGs                Yes                   Yes                       No

  Engeland 1995[@R70]                    Mortality                Nordic countries               1958--1987      20+ years               No                                                     GLM                                                      Not provided              Yes                   No                        No

  Ferlay 2010[@R27]                      Incidence/\              European countries             1978--2002      \<10 years              No                                                     APC model                                                Nordpred                  Yes                   No                        No
                                         mortality                                                                                                                                                                                                                                                                                 

  Ferlay 2013[@R28]                      Incidence/\              European countries             1978--2006      \<10 years              No                                                     APC model                                                Nordpred                  No                    No                        No
                                         mortality                                                                                                                                                                                                                                                                                 

  Ferlay 2013[@R1]                       Incidence/\              Worldwide                      1989--2011      20+ years               No                                                     Assume same rate                                         Not provided              Yes                   No                        No
                                         mortality                                                                                                                                                                                                                                                                                 

  French 2006[@R71]                      Mortality                UK                             1984--2004      10--19 years            No                                                     Joinpoint analysis/GLM                                   Stata, Joinpoint          Yes                   No                        No

  Fukuda 2002[@R72]                      Mortality                Japan                          1988--1997      10--19 years            No                                                     GLM                                                      Not provided              No                    No                        No

  Galasso 2013[@R29]                     Incidence/\              Italy                          1970--2002      10--19 years            No                                                     APC model                                                MIAMOD                    Yes                   No                        No
                                         mortality                                                                                                                                                                                                                                                                                 

  Godlewski 2012[@R73]                   Incidence                Poland                         1999--2008      10--19 years            No                                                     GLM                                                      Stata                     No                    No                        No

  Hakulinen 1994[@R74]                   Incidence                Sweden                         1960--1984      20+ years               No                                                     GLM                                                      GLIM                      Yes                   No                        No

  Heinävaara 2006[@R75]                  Incidence/\              Finland                        1987--1997      10--19 years            No                                                     GLM                                                      Not provided              Yes                   Yes                       Yes
                                         mortality                                                                                                                                                                                                                                                                                 

  Hristova 1997[@R30]                    Incidence                Bulgaria                       1968--1992      20+ years               No                                                     APC model                                                GLIM                      No                    No                        No

  Jee 1998[@R76]                         Mortality                Korea (South)                  1980--1994      10--19 years            No                                                     GLM                                                      Not provided              Yes                   No                        No

  Jürgens 2014[@R31]                     Mortality                Switzerland                    1974--2008      10--19 years            No                                                     Bayesian APC model                                       R, WinBUGs                Yes                   Yes                       Yes

  Kaneko 2003[@R32]                      Mortality                Japan                          1952--2001      20+ years               No                                                     Bayesian APC model                                       WinBUGs                   Yes                   Yes                       No

  Knorr-Held 2001[@R33]                  Mortality                Germany                        1952--1996      10--19 years            Yes, smoking prevalence and consumption                Bayesian APC model and GLM with smoking as a covariate   BAMP                      Yes                   No                        No

  Kubík 1998[@R34]                       Mortality                4 European countries           1960--1989      20+ years               No                                                     APC model                                                GLIM                      Yes                   No                        No

  Kuroishi 1992[@R77]                    Mortality                Japan                          1969--1989      20+ years               No                                                     GLM                                                      Not provided              Yes                   No                        No

  Li 2017[@R35]                          Mortality                China                          1974--2014      10--19 years            No                                                     APC model                                                Nordpred                  No                    No                        Yes

  Malvezzi 2013[@R36]                    Mortality                33 European countries          1970--2009      \<10 years              No                                                     Joinpoint analysis/Bayesian APC model                    R, Joinpoint, GLIM        Yes                   No                        No

  Malvezzi 2015[@R78]                    Mortality                28 European countries          1970--2009      \<10 years              No                                                     Joinpoint analysis/GLM                                   R, Joinpoint              Yes                   No                        No

  Malvezzi 2018[@R100]                   Mortality                6 countries                    1970--2012      \<10 years              No                                                     Joinpoint analysis/GLM                                   Joinpoint                 Yes                   No                        No

  Martín-Sánchez 2016[@R79]              Mortality                Spain                          2007--2013      \<10 years              No                                                     GLM                                                      R, WinBUGs                Yes                   No                        No

  Martín-Sánchez 2017[@R111]             Mortality                Spain                          1980--2013      \<10 years              Yes, smoking prevalence                                GLM                                                      Not provided              Yes                   No                        No

  Martín-Sánchez 2018[@R101]             Mortality                52 countries                   2008--2014      10--19 years            No                                                     GLM                                                      WinBUGs                   No                    No                        No

  Mistry 2011[@R37]                      Incidence                UK                             1975--2007      20+ years               No                                                     APC model                                                Stata, Nordpred           Yes                   Yes                       No

  Møller 2002[@R38]                      Incidence                Nordic countries               1958--1997      20+ years               No                                                     APC model                                                Nordpred                  Yes                   No                        No

  Møller 2005[@R39]                      Incidence                Nordic countries               1958--1987      10--19 years            No                                                     APC model                                                R                         Yes                   No                        Yes

  Møller 2007[@R40]                      Incidence                UK                             1974--2003      20+ years               No                                                     APC model                                                Nordpred                  Yes                   No                        No

  Murray 1997[@R103]                     Mortality                47 countries                   1950--1990      20+ years               Yes, smoking intensity                                 GLM                                                      Not provided              Yes                   No                        No

  Negri 1990[@R41]                       Mortality                Italy                          1955--1984      10--19 years            Yes, smoking prevalence                                APC model involve smoking data                           GLIM                      Yes                   Yes                       No

  Negri 1990[@R42]                       Mortality                Switzerland                    1950--1984      10--19 years            Yes, smoking prevalence                                APC model involve smoking data                           GLIM                      Yes                   Yes                       No

  Ng 2009[@R104]                         Mortality                Indonesia, Vietnam, Ethiopia   2005--2006      10--19 years            Yes, smoking prevalence                                GLM                                                      SAS, Stata                No                    No                        No

  Nowatzki 2011[@R43]                    Incidence                Canada                         1976--2005      20+ years               No                                                     APC model                                                Nordpred                  Yes                   No                        No

  Oberaigner 2014[@R80]                  Incidence                Austria                        1990--2009      10--19 years            No                                                     GLM                                                      Stata                     Yes                   Yes                       No

  Olajide 2015[@R81]                     Incidence                UK                             2002--2011      \<10 years              No                                                     GLM                                                      SAS, Stata                Yes                   Yes                       No

  O\'Lorcain 2004[@R82]                  Mortality                Ireland                        1954--2000      10--19 years            No                                                     GLM                                                      Stata                     Yes                   No                        No

  Olsen 2008[@R44]                       Mortality                UK                             1971--2005      20+ years               No                                                     APC model                                                Nordpred                  Yes                   No                        No

  Parsons 2000[@R83]                     Incidence                UK                             1981--1995      20+ years               No                                                     GLM                                                      S-PLUS                    Yes                   Yes                       No

  Pearce 2016[@R93]                      Mortality                Ireland                        2007--2011      10--19 years            No                                                     Assume same rate                                         SAS                       Yes                   No                        No

  Pierce 1992[@R105]                     Mortality                8 countries                    1975--1986      10--19 years            Yes, tobacco consumption                               The simple tobacco consumption model                     Not provided              No                    No                        No

  Pisani 1993[@R94]                      Mortality                24 geographical global areas   1985--1985      10--19 years            No                                                     Assume same rate                                         Not provided              No                    No                        No

  Pompe-Kirn 2000[@R45]                  Incidence                Slovenia                       1965--1994      10--19 years            No                                                     APC model                                                GLIM                      Yes                   No                        No

  Preston 2014[@R106]                    Mortality                USA                            1940--2009      20+ years               Yes, smoking prevalence                                GLM                                                      Not provided              Yes                   No                        No

  Quante 2016[@R95]                      Incidence/\              Germany                        1998--2012      10--19 years            No                                                     Joinpoint analysis/annual percentage change              SAS, Joinpoint            Yes                   No                        No
                                         mortality                                                                                                                                                                                                                                                                                 

  Rahib 2014[@R96]                       Incidence/\              USA                            2006--2010      20+ years               No                                                     Annual percentage change                                 Joinpoint                 Yes                   No                        No
                                         mortality                                                                                                                                                                                                                                                                                 

  Rapiti 2014[@R46]                      Incidence                Switzerland                    1985--2009      10--19 years            No                                                     APC model                                                Nordpred                  Yes                   No                        No

  Reissigova 1994[@R47]                  Mortality                Czech Republic                 1960--1989      10--19 years            No                                                     APC model                                                GLIM                      No                    Yes                       No

  Ribes 2014[@R48]                       Incidence/\              Spain                          1993--2007      10--19 years            No                                                     Bayesian APC model                                       INLA                      Yes                   No                        No
                                         mortality                                                                                                                                                                                                                                                                                 

  Riebler 2017[@R49]                     Mortality                5 countries                    1950--2011      10--19 years            No                                                     Bayesian APC model                                       R, WinBUGs, INLA          Yes                   Yes                       Yes

  Rutherford 2012[@R50]                  Incidence                Finland                        1957--1987      20+ years               No                                                     APC model                                                Stata                     Yes                   Yes                       Yes

  Sánchez 2010[@R51]                     Incidence/\              Spain                          1981--2006      \<10 years              No                                                     APC model                                                MIAMOD                    Yes                   Yes                       No
                                         mortality                                                                                                                                                                                                                                                                                 

  Shamseddine 2014[@R84]                 Incidence                Lebanon                        2003--2008      10--19 years            No                                                     Joinpoint analysis/GLM                                   Joinpoint                 No                    No                        No

  Sharp 1996[@R52]                       Incidence/\              UK                             1968--1992      \<10 years              No                                                     APC model                                                GLIM                      Yes                   No                        No
                                         mortality                                                                                                                                                                                                                                                                                 

  Shibuya 2005[@R7]                      Mortality                Four countries                 1950--2000      20+ years               Yes, tobacco consumption and tar content               GLM with smoking as a covariate                          Not provided              Yes                   Yes                       Yes

  Smith 2009[@R97]                       Incidence                USA                            2003--2005      20+years                No                                                     Assume same rate                                         SAS                       Yes                   No                        No

  Smittenaar 2016[@R53]                  Incidence/mortality      UK                             1979--2014      20+years                No                                                     APC model                                                Stata                     Yes                   Yes                       No

  Son 2016[@R54]                         Mortality                Korea (South)                  1983--2012      20+years                No                                                     APC model                                                Nordpred                  Yes                   No                        No

  Stoeldraijer 2015[@R107]               Mortality                4 European countries           1950--2009      20+years                Yes, smoking prevalence                                APC model / SAF                                          R                         Yes                   No                        No

  Stracci 2013[@R55]                     Incidence/\              Italy                          1970--2002      10--19 years            No                                                     APC model                                                MIAMOD                    Yes                   No                        No
                                         mortality                                                                                                                                                                                                                                                                                 

  Strong 2008[@R108]                     Mortality                107 countries                  1950--2002      20+years                Yes, smoking intensity                                 GLM                                                      Not provided              No                    No                        No

  Swaminathan 2011[@R56]                 Incidence                India                          1982--2006      10--19 years            No                                                     APC model                                                Nordpred                  Yes                   No                        No

  Torres-Avilés 2015[@R85]               Mortality                Chile                          1990--2009      \<10 years              No                                                     GLM                                                      WinBUGs                   Yes                   Yes                       Yes

  Tsoi 2017[@R86]                        Incidence                China                          1993--2007      20+years                No                                                     GLM                                                      R                         Yes                   Yes                       No

  Vardanjani 2017[@R98]                  Incidence                Iran                           2003--2009      \<10 years              No                                                     Joinpoint analysis/annual percentage change              Joinpoint                 No                    No                        No

  Virani 2017[@R57]                      Incidence                Thailand                       1989--2012      10--19 years            No                                                     Joinpoint analysis/APC model                             R, Joinpoint, Nordpred    No                    Yes                       No

  Vogt 2017[@R112]                       Mortality                German                         1956--2013      20+years                Yes, years smoked                                      GLM                                                      Not provided              Yes                   No                        No

  Weir 2015[@R58]                        Incidence                USA                            1975--2009      10--19 years            No                                                     APC model                                                Nordpred                  Yes                   No                        No

  Wiklund 1992[@R87]                     Mortality                Sweden                         1975--1984      20+years                No                                                     GLM                                                      CAN\*TROL                 Yes                   No                        No

  Winkler 2015[@R109]                    Mortality                South Africa                   2010            10--19 years            Yes, smoking prevalence                                GLM/relative risk for smokers                            Not provided              No                    No                        No

  Yabroff 2008[@R99]                     Mortality                USA                            1999--2003      10--19 years            No                                                     Assume same rate                                         Not provided              Yes                   No                        No

  Yang 2004[@R89]                        Mortality                China                          1990--1999      \<10 years              No                                                     GLM                                                      Not provided              No                    Yes                       No

  Yang 2005[@R88]                        Incidence                China                          1993--1997      \<10 years              No                                                     GLM                                                      GLIM                      No                    No                        No
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*The majority of observed data used are included in the Cancer Incidence in Five Continents series published by the International Agency for Research on Cancer, or have high population coverage as stated in WHO mortality database.

†Provides fitted values of observed data to allow appraisal of the model fit to the observed data.

‡Validation using observed data: Paper compared the projected values with the observed data beyond the period included in model fitting. The model was validated by excluding data for the most recent years from the model fitting, and then compared the projected rates for those years with the observed data.

APC, age--period--cohort; GLM, generalised linear model; SAF, smoking attributable fraction.

###### 

Summary of study characteristics grouped according to projection method used

  Method                                                           Total studies\*   Incidence     Mortality    ≥10 years observed data   Good data quality†   No of years projected   Provide fitted values‡   Validation§                
  ---------------------------------------------------------------- ----------------- ------------- ------------ ------------------------- -------------------- ----------------------- ------------------------ ------------- ------------ --------
  **Methods without smoking factor, (%)**                          **88**            **50**        **55**       **75**                    **71**               **15**                  **57**                   **16**        **23**       **11**
  (**87.1**)                                                       (**56.8**)        (**62.5**)    (**85.2**)   (**80.7**)                (**17.0**)           (**64.8**)              (**18.2**)               (**26.1**)    (**12.5**)   
  APC models, (%)[@R2]                                             44                26            29           44                        37                   6                       31                       7             15           8
  (**43.6**)                                                       (59.1)            (65.9)        (100.0)      (84.1)                    (13.6)               (70.5)                  (15.9)                   (34.1)        (18.2)       
  Other GLMs, (%)[@R18]                                            35                17            21           30                        29                   10                      20                       5             8            3
  (**34.7**)                                                       (48.6)            (60.0)        (85.7)       (82.9)                    (28.6)               (57.1)                  (14.3)                   (22.9)        (8.6)        
  Present state methods, (%)[@R1]                                  12                7             8            4                         8                    1                       7                        4             0            0
  (**11.9**)                                                       (58.3)            (66.7)        (33.3)       (66.7)                    (8.3)                (58.3)                  (33.3)                   (0.0)         (0.0)        
  **Methods incorporating smoking data, (%)**                      **16**            **2**         **16**       **13**                    **11**               **1**                   **7**                    **8**         **5**        **1**
  (**15.8**)                                                       (**12.5**)        (**100.0**)   (**81.3**)   (**68.8**)                (**6.3**)            (**43.8**)              (**50.0**)               (**31.3**)    (**6.3**)    
  GLM with a smoking variable as one of the covariates, (%)[@R3]   8                 0             8            8                         7                    1                       1                        6             3            1
  (**7.9**)                                                        (0.0)             (100.0)       (100.0)      (87.5)                    (12.5)               (12.5)                  (75.0)                   (37.5)        (12.5)       
  APC model including an effect for smoking, (%)[@R41]             2                 0             2            2                         2                    0                       2                        0             2            0
  (**2.0**)                                                        (0.0)             (100.0)       (100.0)      (100.0)                   (0.0)                (100.0)                 (0.0)                    (100.0)       (0.0)        
  Projections adjusted for the SAF, (%)[@R102]                     2                 1             2            2                         2                    0                       1                        1             0            0
  (**2.0**)                                                        (50.0)            (100.0)       (100.0)      (100.0)                   (0.0)                (50.0)                  (50.0)                   (0.0)         (0.0)        
  Other methods, (%)[@R104]                                        4                 1             4            1                         0                    0                       3                        1             0            0
  (**4.0**)                                                        (25.0)            (100.0)       (25.0)       (0.0)                     (0.0)                (75.0)                  (25.0)                   (0.0)         (0.0)        
  **Total, (%)**                                                   **101**           **52**        **68**       **85**                    **79**               **16**                  **61**                   **24**        **26**       **12**
  (**100.0**)                                                      (**51.5**)        (**67.3**)    (**84.2**)   (**78.2**)                (**15.8**)           (**60.4**)              (**23.8**)               (**25.7**)    (**11.9**)   

\*Numbers of studies are not mutually exclusive, with six studies using more than one method.

†The majority of observed data used are included in the Cancer Incidence in Five Continents series published by the International Agency for Research on Cancer, or have high population coverage as stated in WHO mortality database.

‡Provides fitted values of observed data to allow appraisal of the model fit to the observed data.

§Validation using observed data: Paper compared the projected values with the observed data beyond the period included in model fitting. The model was validated by excluding data for the most recent years from the model fitting, and then compared the projected rates for those years with the observed data.

APC, age--period--cohort; GLM, generalised linear model; SAF, smoking attributable fraction.

The majority of models were developed using more than 10 years of observed data that was considered to be good quality, that is, incidence data included in the Cancer Incidence in Five Continents series,[@R15] or mortality data from a source considered by WHO to have a high population coverage.[@R113] Most studies provided projections for 10 years or more, and the proportion of studies providing projections for more than 19 years was higher for studies using methods incorporating data on smoking (50.0%) than for studies using methods which did not incorporate smoking patterns (18.2%). Only 25.7% of the studies provided comparisons of fitted and observed rates and 11.9% of the studies reported validation of the projection model using observed data.

The numbers of studies by publication period and by the country's HDI rank are presented in [figure 3](#F3){ref-type="fig"}. The number of publications increased substantially over time, especially the number of studies using APC models, which more than tripled in the most recent period (2008--2018) compared with 1998--2007. The majority of the articles included in this systematic review used data from countries with very high or high HDI including studies from the USA, Europe and Australia, 16 studies used data from countries in medium or low HDI groups including studies from China and India, and 22 studies used data from multiple countries.

![Studies included by year of publication, 1988--2018 and level of human development of the country providing the data, stratified by method. \*Six studies used more than one method, and 22 studies used data from multiple countries. HDI, Human development index.](bmjopen-2018-028497f03){#F3}

The statistical software packages used by method and year of publication are shown in [figure 4](#F4){ref-type="fig"}. Among the studies using APC models, the most commonly used software package was Nordpred (R package developed by Harald Fekjær and Bjørn Møller, Cancer Registry of Norway)[@R10] and most of these studies were published in recent years. GLIM (Oxford, UK)[@R114] was the second most commonly used software for APC modelling, but it was mainly used in the earlier years, with the latest study published in 2000.[@R45] Special software WinBUGS (Cambridge, UK),[@R115] INLA (R package developed by Rue and Martino, Department of Mathematical Sciences NTNU, Norway)[@R116] or BAMP (Institute of Biomedical Engineering, Imperial College, London, UK)[@R117] were used for studies employing Bayesian methods.[@R2] Among studies using other GLMs, Joinpoint (National Cancer Institute, USA)[@R118] and Stata[@R119] were the two most commonly used software packages. Most studies using the present state method did not mention which software was used. Nordpred, Stata, Joinpoint, SAS,[@R120] other R packages and WinBUGS were the software program most commonly used in the recent time period. An overview of these software packages is provided in [table 5](#T5){ref-type="table"}. Each of these packages has different features and some are freely available to researchers.

![Statistical software packages used by method and year of publication. \*Six studies used more than one method, 20 studies used more than one software package. \*\*Others include BMDP, BAMP, S-Plus, S and Can\*Trol.](bmjopen-2018-028497f04){#F4}

###### 

Summary of software packages commonly used in 2008--2018

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Methods group      Software/\       Free software   References                                                                                                                                                                                                                                                      Descriptions                                                                                                                                                                                                                                                                                                Programming requirement
                     package                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  ------------------ ---------------- --------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  APC model          Nordpred[@R10]   Yes             [@R9]                                                                                                                                                                                                                                                           Nordpred is an R package for projection up to 25 years, based on log-link or the power 5 model, and provide significance test for use of recent slope or average slope for the whole period. Requires specific data format by 5-year age group and 5-year period and cannot incorporate other covariates.   Requires a specific data format and basic R programming. Assumes that the last non-linear period component applies to all future periods, and the non-linear cohort component was projected for estimated cohorts.

  Stata[@R122]       No               [@R37]          User-written command, published packages include 'apcfit'[@R122] and 'apcspline'[@R124] using restricted cubic splines, and the latter command has not been used for lung cancer projections. Can be used with single year data or 5-year grouped data.         Apcfit requires some programming when projecting beyond the observed data. User defines the number of knots for age, period and cohort, therefore involves model selection and comparison.                                                                                                                  

  R-other[@R9]       Yes              [@R26]          Other packages include 'Epi'[@R9] and 'apcfit'[@R123] which incorporate a smoothing method and the lexis diagram method. Can be used with single year data or 5-year grouped data. Allows user to adjust the boundary knot for period and cohort projections.   Requires R programming when projecting beyond the observed data. User defines the number of knots for age, period and cohort, and allows user to specify the centering of period and cohort.                                                                                                                

  WinBUGS[@R115]     Yes              [@R9]           Commonly used for Bayesian models, with Markov Chain Monte Carlo (MCMC) techniques. Trends for age, period and cohort effects are smoothed. MCMC is inherently less robust than analytic statistical methods. There is no in-built protection against misuse.   Requires knowledge of Bayesian methods including recognition of the importance of prior distributions.                                                                                                                                                                                                      

  GLM                Stata[@R119]     No              [@R65]                                                                                                                                                                                                                                                          Stata's glm fits GLMs by using either maximum quasi likelihood or Newton-Raphson (maximum likelihood) optimisation, which is the default.                                                                                                                                                                   Requires basic programming and user can define link functions, distributions, or perform analyses via a menu.

  SAS[@R120]         No               [@R63]          SAS's genmod procedure fits a GLM to the data by maximum likelihood estimation of the parameter vector beta.                                                                                                                                                    Requires some SAS programming experience.                                                                                                                                                                                                                                                                   

  Joinpoint[@R118]   Yes              [@R18]          Analyse Joinpoint models based on linear or log-linear regression, the tests of significance for change in trend use a Monte Carlo Permutation method.                                                                                                          No programming required. Can be easily learnt using the sample analyses provided on their website.                                                                                                                                                                                                          
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

APC, age-period-cohort; GLM, generalised linear model.

Discussion {#s4}
==========

This review highlights the scope and diversity of the statistical methods used to project lung cancer rates for the longer term, and provides a summary of the main methods used in studies conducted over the last three decades. These methods range from using a basic assumption that the current rate will remain unchanged into the future, to more complex statistical models involving a range of different assumptions, statistical techniques and software packages. We found that both lung cancer incidence and mortality projections were commonly based solely on past cancer trends, and only a limited number of studies incorporated smoking data in the projection models, most likely due to the scarcity of data on past smoking behaviour in the population.[@R21] Methods, which do not incorporate smoking data, are also generalisable to projections for other cancer types. We found that the number of studies reporting statistical projections for lung cancer increased substantially over time, and that the majority of these studies used good quality data from countries with a very high or high level of HDI.

The three-factor APC model was the most commonly used method for projecting lung cancer rates. This method does not require knowledge of aetiological factors,[@R25] as the period and cohort effects are considered to be surrogates for exposure to a range of risk factors.[@R11] For example, period effects can reflect diagnostic and treatment factors, which lead to changes in disease incidence and survival across all age groups.[@R11] On the other hand, the cohort effect may represent risk factors such as smoking behaviour that change from generation to generation.[@R7] This method is considered to be appropriate for long-term projections.[@R10] However, due to the non-identifiability of the linear components of the age, period and cohort parameter estimates, there is no way to distinguish the period effect and the cohort effect. This non-identifiability issue for APC models can be addressed by introducing constraints to the time effects, however, the parameter estimates can be sensitive to the choice of constraint on period and cohort factors.[@R3] In addition, the APC model used in this context generally assumes that current and past trends continue into the future, and such an assumption would be questionable if any interventions have significant impacts on the cancer rates. Given the latency period between exposure to a cancer agent and development of some cancers, projections that are based on past trends may be inaccurate.[@R8] Nonetheless, with the development of strategies to deal with the inherent non-identifiability problem in such models, the APC model has been implemented in various statistical software packages in recent years.[@R10]

In contrast to the APC model, other methods using GLMs do not include all three time components in the same model, making them less complicated to use. GLMs are more flexible and can be easily implemented using commonly available software including Stata,[@R119] SAS,[@R120] R and Joinpoint. The interpretation of the results from the standard GLM seems to be straightforward, and it can be extended to incorporate other factors.[@R125] This method has been evaluated using Finnish Cancer Registry data and it was concluded that the GLM performed reasonably well for short-term (eg, 5 years) projections.[@R125] However, GLMs may not be appropriate for long-term projections (\>10 years) as the model does not consider period and cohort effects at the same time. For example, a GLM without a cohort component may not be appropriate for cancer types where significant changes in risk factors have occurred, due to the lack of cohort-specific effects in the projections.[@R125] On the other hand, a GLM without a period component will not be able to capture the changes in period effects for cancer types with screening programme or improvements in treatments over time.[@R33] It is recommended that the potential significance of period and cohort effects should be examined and determined prior to implementing any projections using GLMs.[@R9]

The present state method is the simplest projection method, which projects future numbers of lung cancer cases or deaths by applying the average of the age-specific incidence/mortality rates observed in the most recent years to the projected future age-specific population estimates. The projection is based on a very strong assumption that the rates will remain constant over the projection period, which could be 20 or 30 years long. This method does not need special software, and it is a practical method to use when long-term historical data are not available. Although the validity of this assumption may not be realistic, especially for long-term projections, the results of present state projections can provide base assumptions from which to examine the impact of population growth and ageing on the cancer burden, and can provide a benchmark which is useful for evaluating the effect of cancer prevention or intervention activities.

Due to the association between tobacco smoking and lung cancer risk,[@R4] past smoking behaviour is considered to be an important predictor for lung cancer rates.[@R3] The accuracy of lung cancer projections can, therefore, be improved if historical data on smoking exposure in the population are incorporated into the models. This is likely to be particularly important if smoking trends peak and then reverse over time, as has occurred in a number of high-income countries,[@R126] since the simple projection of lung cancer trends based only on data reflecting the burgeoning epidemic will not reflect the impact of a turnaround in smoking prevalence.[@R3] However, our review found that only a very limited number of published studies incorporated smoking data in the projection models, with only eight studies including detailed historical data on smoking exposure along with lung cancer data in their projection models.[@R3] Another eight studies used less detailed information or a limited amount of smoking data, which was not directly included in the projection models.[@R41] Negri *et al* developed a method to incorporate smoking patterns into an APC model, multiplying the estimated period parameters by predefined coefficients based on recent trends in smoking prevalence and the tar yield of cigarettes.[@R41] Two studies reported projections adjusted for the SAF, which involved modelling projections based on observed cancer data and then modifying the projected rates by multiplying by the SAF, which was estimated from a previous population-based study.[@R102] This method can be used for data from any country where lung cancer is primarily caused by smoking,[@R107] but is more suitable for countries where lung cancer mortality for males had reached its peak some time ago and recent smoking prevalence is similar for males and females.[@R107] In addition, it should be noted that the SAF based on the relative risk of death for current smokers estimated by the American Cancer Society's Cancer Prevention Study II (ACS CPS-II) in the USA may not be applicable to other countries.[@R107] A few other studies used methods which were based on cancer rates reported in the literature or on less detailed data,[@R104] these methods are useful for countries where it is not realistic to use more sophisticated models due to the lack of detail in the available cancer and smoking data. However, for projections in populations at an earlier stage in the smoking epidemic more detailed information on tobacco exposure would be necessary so that the complex changes over time in the smoking behaviour of the population are captured.[@R127]

As previously discussed, GLMs are flexible and can be extended to incorporate other covariates, including smoking exposure, at the requisite level of detail. Log-linear models assuming a Poisson distribution based on age, cohort and cigarette tar exposure were reported by Brown and Kessler[@R3] using data from the USA, and by Shibuya *et al* [@R7] using data for four countries---the USA, UK, Canada and Australia. Both studies were based on sex-specific tobacco consumption over time for two large age groups (30--49 years and ≥50 years).[@R3] These studies take into account the effects of changes in tobacco consumption and differences in exposure among birth cohorts, and both studies demonstrated improvements in projections by incorporating tar exposure measurements into the projection models. This approach was also reported by Knorr-Held and Rainer[@R33] using data from Germany, but they concluded that the available smoking data in Germany were not able to improve their projections, because there was no available information on sex-specific cigarette consumption, nor on the average tar content per cigarette. This confirmed that accurate projections and the selection of appropriate projection methods depend on the quality and availability of data at the requisite level of detail. Some other smoking-related variables have also been used, including smoking intensity[@R103] and the number of years of smoking prior to age 40.[@R106] All the studies using GLMs did not include constraints on the period and cohort components. This method has the advantage of flexibility and is able to piecewise examine the performance of various models based on different covariates, which is particularly relevant when detailed data on risk factors are available. However, the application of this method for a specific cancer type requires reasonable justification and validation, to ensure that the covariates included in the projection model are sufficient to reflect the factors that impact cancer rates in the population. In addition, the potential risk of ecological bias should be considered.

The availability of suitable software is paramount when dealing with complex models and inferences, such as when using APC models. The increasing number of studies using APC models is likely to be due to recent developments in statistical software packages including R and Stata. Norpred is a free-software package in R and S-PLUS for APC modelling which was developed by Møller *et al* at the Cancer Registry of Norway.[@R10] It incorporates a smoothing technique and has become the most commonly used software for fitting APC models in recent years. However, Norpred only provides projections for a maximum of 25 years beyond the observed data, and no other covariates can be incorporated into the model. Other R packages, including 'Epi',[@R9] 'apc'[@R123] and 'INLA',[@R48] can also be used for cancer incidence or mortality projections. Two packages in Stata were developed for APC models in the early 2010s and have the advantage of more flexible modelling implementation,[@R122] although one package requires additional programming when projecting beyond the observed data.[@R122] Joinpoint[@R118] is another popular package that has been increasingly used to project cancer rates into the future by extrapolating the most recent trend.[@R128] However, Joinpoint is only considered to be suitable for short-term projections.[@R118]

We acknowledge that each method included in this review has its own merits and limitations depending on the length of projections, data quality and availability, and the timing of analysis in relation to different stages of the smoking epidemic in a country (particularly, whether smoking prevalence is assumed to peak over the time frame of the analysis). It is important to note that all projections of cancer incidence and mortality based on historical trends may be inaccurate, regardless of the method used, if the underlying trends in risk or interventions change.[@R9] This is particularly relevant to lung cancer due to its strong relationship with tobacco exposure.[@R8] There is no way to identify the 'best model' for all situations or to conclude that one method is superior to another. Furthermore, even projections using the same method can be sensitive to the model setting and the length of the projection base.[@R10] Therefore, wherever possible, appropriate validation of the selected projection method should be performed, as such information is useful for checking the specifications of the model and helps researchers understand the potential limitations of the projection model. Performing a validation of the model being used for a projection by withholding the most recent observed data from the model fitting and then comparing the projected with the observed rates for the most recent period, can provide important information on the performance of the projection model.[@R7] Surprisingly, however, fewer than 12% of the studies reported on this, although as high-quality data on lung cancer rates is now available for several decades or longer for many countries it is likely that this type of validation will become more feasible and more frequently performed. In addition, as more data become available over time, prior statistical projections can be compared against the emergent data, which will allow for even greater understanding of the general strengths and pitfalls of the various methods---this exercise is underway and will yield further insights.

Strengths and weaknesses {#s4-1}
------------------------

Although we searched multiple electronic databases (Medline, Embase and PreMEDLINE databases), this review is limited to studies published in English. Thus, this review may not be complete if there were relevant studies published in other languages. It is also possible that we may have missed articles in the initial search, as we were unable to search the grey literature completely for eligible studies. It should also be noted that this review is limited to lung cancer only (International Classification of Diseases 10th Revision, ICD 10 C33--C34), which means it will not capture the literature on every possible type of cancer related to the lungs (eg, mesothelioma). In addition, the wide variability in study populations and time periods made meta-analyses infeasible. Despite these potential limitations, we believe this review is still a valuable resource and has many strengths. By searching the reference lists of all included articles, we should have ensured a thorough and extensive coverage of the literature, and developing prespecified assessment criteria to provide clear definitions for the different assessment areas allowed for objective assessment of the studies. Also, a pretested and revised standardised form was used for data extraction, which should have minimised differences between the data extraction by different reviewers, as confirmed by the high agreement for the data extracted by the two reviewers (91.6%). Also, we developed an organisational framework to categorise and summarise the projection methods used in the literature, which provides the comprehensive information and highlights the similarities and differences across methods. To our knowledge, this systematic review is the first to provide comprehensive, up-to-date coverage of the literature on statistical methods for projecting lung cancer rates.

Implications for research {#s4-2}
-------------------------

This systematic review provides a comprehensive summary of the statistical methods over the past three decades used in published lung cancer incidence or mortality projections. The assessment of the strengths and advantages of existing methods will help researchers to better understand the currently used statistical methods for projecting lung cancer rates. In this review, we summarised both theoretical and practical aspects, including software information and generalisability of the methods, and some of the common methods described in this review can be applied to other cancer types, so it is hoped that this review will serve as a resource for researchers who are interested in using or developing one or more of these methods for projecting cancer rates. In particular, the methods incorporating a covariate such as smoking may be also applicable to projection of rates for other cancers with data on risk factors or diagnostic factors at the requisite level of detail, such as prostate specific antigen (PSA) testing rates for prostate cancer.
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